quinazolines has been researched along with cudc 101 in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (73.68) | 24.3611 |
| 2020's | 5 (26.32) | 2.80 |
| Authors | Studies |
|---|---|
| Atoyan, R; Bao, R; Cai, X; DellaRocca, S; Forrester, J; Keegan, M; Lai, CJ; Munger, WE; Pepicelli, CV; Qian, C; Qu, H; Samson, M; Tao, X; Wang, DG; Wang, J; Xu, GX; Yin, L; Zhai, HX; Zifcak, B | 1 |
| Seo, SY | 1 |
| Atoyan, R; Bao, R; Borek, M; Cai, X; DellaRocca, S; Lai, CJ; Ma, AW; Qian, C; Qu, H; Samson, M; Voi, M; Wang, DG; Wang, J; Xu, GX; Yin, L; Zhai, HX; Zifcak, B | 1 |
| Atoyan, R; Cai, X; Lai, CJ; Ma, AW; Pursell, NW; Samson, ME; Savagner, P; Selmi, A; Voi, M; Wang, J; Xu, W | 1 |
| Gao, QS; Guo, Q; Hong, Y; Jin, JX; Jin, L; Kang, JD; Li, S; Yan, CG; Yin, XJ; Zhu, HY | 1 |
| Ma, J; Wang, X; Wen, C; Xiang, Z; Zhang, Q | 1 |
| Beeram, M; Chambers, G; Laliberte, R; LoRusso, PM; Ma, A; Mays, TA; Papadopoulos, KP; Patnaik, A; Rasco, DW; Shimizu, T; Smith, LS; Tolcher, AW; Voi, M; Wang, J | 1 |
| Hsiao, SH; Hsieh, CH; Huang, CW; Huang, YH; Li, YQ; Luo, SY; Su, CY; Wu, CP | 1 |
| Atoyan, R; Bauman, JE; Burtness, B; Colevas, AD; Galloway, TJ; Gilbert, J; Jimeno, A; Ma, AW; Mehra, R; Raben, D; Saba, NF; Wang, J; Wirth, LJ | 1 |
| Boufraqech, M; Boxer, MB; Copland, JA; Davis, S; Kebebew, E; Kiefer, JA; Li, Z; Mehta, A; Shen, M; Smallridge, RC; Tian, Z; Wang, J; Yu, Z; Zhang, L; Zhang, Y | 1 |
| Boufraqech, M; Kebebew, E; Lake, R; Zhang, L | 1 |
| Mancini, MA; Marcelli, M; Mediwala, SN; Sun, H; Szafran, AT | 1 |
| Biswas, L; Keechilat, P; Melge, AR; Mohan, CG; Panicker, PS | 1 |
| Anastasov, N; Atkinson, MJ; Kell, R; Moertl, S; Payer, S; Winkler, K | 1 |
| Fang, Q; Lu, T; Ma, D; Wang, J; Wang, W; Wei, D; Yu, K; Zhang, T; Zhang, Z | 1 |
| Petkova, A; Schätzlein, AG; Soundararajan, R; Uchegbu, IF; Wang, G | 1 |
| Abuo-Rahma, GEA; Badr, M; Bass, AKA; El-Zoghbi, MS; Mohamed, MFA; Nageeb, EM | 1 |
| Cui, R; Ji, M; Jin, SY; Li, H | 1 |
| An, L; Chu, C; Li, L; Li, X; Liu, Q; Wang, R; Wang, Y; Wang, Z; Wei, X; Wu, G; Zhang, G | 1 |
1 review(s) available for quinazolines and cudc 101
| Article | Year |
|---|---|
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Benzimidazoles; Cyclic Nucleotide Phosphodiesterases, Type 5; Daunorubicin; Doxorubicin; fms-Like Tyrosine Kinase 3; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Targeted Therapy; Morpholines; Nicotinamide Phosphoribosyltransferase; Nitric Oxide; Pyrimidines; Quinazolines; Structure-Activity Relationship; Transcription Factors | 2021 |
2 trial(s) available for quinazolines and cudc 101
| Article | Year |
|---|---|
Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Combined Modality Therapy; Drug Administration Schedule; ErbB Receptors; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2014 |
A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; ErbB Receptors; Female; Head and Neck Neoplasms; Histone Deacetylases; Humans; Hydroxamic Acids; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Radiotherapy; Receptor, ErbB-2; Squamous Cell Carcinoma of Head and Neck | 2015 |
16 other study(ies) available for quinazolines and cudc 101
| Article | Year |
|---|---|
CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; ErbB Receptors; Estrogen Receptor alpha; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mice; Mice, Nude; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Growth Factor; Signal Transduction; Xenograft Model Antitumor Assays | 2010 |
Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery.
Topics: Antineoplastic Agents; Drug Combinations; Drug Discovery; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Structure; Molecular Targeted Therapy; Neoplasms; Quinazolines | 2012 |
Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
Topics: Animals; Apoptosis; Blotting, Western; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Enzyme Inhibitors; Female; HCT116 Cells; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Mice; Mice, Nude; Mice, SCID; Morpholines; Neoplasms; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines; Sf9 Cells; Signal Transduction; Tumor Burden; Vorinostat; Xenograft Model Antitumor Assays | 2012 |
Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion.
Topics: Cadherins; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Neoplasm Invasiveness; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms | 2013 |
CUDC-101, a histone deacetylase inhibitor, improves the in vitro and in vivo developmental competence of somatic cell nuclear transfer pig embryos.
Topics: Animals; Cellular Reprogramming; Embryo Transfer; Embryo, Mammalian; Embryonic Development; Enzyme Inhibitors; Female; Histones; Hydroxamic Acids; Microscopy, Fluorescence; Pregnancy; Quinazolines; Swine | 2014 |
Determination of CUDC-101 in rat plasma by liquid chromatography mass spectrometry and its application to a pharmacokinetic study.
Topics: Administration, Intravenous; Animals; Calibration; Chromatography, Liquid; Histone Deacetylase Inhibitors; Hydroxamic Acids; Male; Quinazolines; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2014 |
Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; ErbB Receptors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasm Proteins; Quinazolines; Receptor, ErbB-2 | 2014 |
Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Cell Cycle; Cell Line, Tumor; DNA, Neoplasm; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; High-Throughput Screening Assays; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mice; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Small Molecule Libraries; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mutation; Oligopeptides; Poly(ADP-ribose) Polymerases; Quinazolines; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | 2016 |
CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy.
Topics: Androgen Receptor Antagonists; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Gene Silencing; Genetic Variation; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Quinazolines; Receptors, Androgen; Signal Transduction; Transcription, Genetic; Xenograft Model Antitumor Assays | 2016 |
Epidermal growth factor receptor (EGFR) structure-based bioactive pharmacophore models for identifying next-generation inhibitors against clinically relevant EGFR mutations.
Topics: Antineoplastic Agents; Computer-Aided Design; Databases, Pharmaceutical; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hydroxamic Acids; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors; Quantitative Structure-Activity Relationship; Quinazolines; Small Molecule Libraries | 2017 |
Comparison of Radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in Pancreatic Cancer Cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Pancreatic Neoplasms; Quinazolines; Radiation-Sensitizing Agents | 2019 |
CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Biomarkers, Tumor; Caspases; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Prognosis; Quinazolines; Retinoic Acid Receptor alpha; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Hyaluronidase Coated Molecular Envelope Technology Nanoparticles Enhance Drug Absorption via the Subcutaneous Route.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Chitosan; Drug Carriers; Drug Delivery Systems; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Hyaluronoglucosaminidase; Hydrophobic and Hydrophilic Interactions; Hydroxamic Acids; Mice; Mice, Nude; Microscopy, Electron, Transmission; Nanoparticles; Particle Size; Polymers; Quinazolines; Rats; Solubility; Xenograft Model Antitumor Assays | 2020 |
CUDC-101 enhances the chemosensitivity of gemcitabine-treated lymphoma cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Quinazolines; Signal Transduction | 2021 |
CUDC‑101 is a potential target inhibitor for the EGFR‑overexpression bladder cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Quinazolines; Urinary Bladder Neoplasms | 2023 |